Published in Obesity and Diabetes Week, September 27th, 2004
According to published research from France, "Since their launch on the French market in 2002, thiazolidinediones ('glitazones') prescribing conditions and therapeutic indications have progressively widened, although remaining strictly defined by the marketing license. Clinical efficacy on glycemic control (HbA1c and glycemia), as well as beneficial metabolic effects (on lipids, insulin resistance, and beta-cellular function) are now well established. Their side effects, generally minor or mild, are also well known."
"The problem of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week